Fax: 47 67 12 26 58
97 articles with Targovax
An 18-month analysis shows that median Overall Survival will be at least 18.2 months for first-line patients receiving ONCOS-102 plus chemotherapy, compared to mOS of 14.2 months or less in the chemotherapy-only control group ONCOS-102-treated patients show broad and powerful immune activation, associated with better survival outcome
Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that the poster " A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma - 12-month analysis of
Targovax ASA, a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces its third quarter 2020 results.
Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, announces the formation of a new Scientific Advisory Board.
Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, announces that an abstract on the mesothelioma trial has been accepted and will be presented at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting, 9 -14 November 2020.
Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer
The pre-defined disease control efficacy threshold in ovarian cancer was not met and this cohort will be closed for enrollment
Targovax ASA, a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, announce that the European Patent Office has granted European Patent no 3293201.
Oblique Therapeutics and Targovax Enter Collaboration to Target Mutant RAS Cancers by Combining Their ONCOS and Abiprot™ Platforms
Oblique Therapeutics and Targovax will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and AbiprotTM technology platforms
Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses
Targovax and Leidos will jointly explore the potential of combining their ONCOS and MicrotideTM technology platforms
Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO
The abstract describes the dose-escalation part of the ONCOS-102 and durvalumab combination trial in peritoneal malignancies
Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO
Targovax ASA announces that interim phase I clinical data from the phase I/II trial evaluating systemic durvalumab + intraperitoneal ONCOS-102 in patients with peritoneal disease originating from ovarian or colorectal cancer, will be presented at the ASCO20 Virtual Scientific conference, 29-31 May 2020.
Progression free survival at the 9-month follow-up is tracking in line with previously published data
Targovax ASA announces the appointment of Dr Victor Levitsky, MD, PhD as Chief Scientific Officer.
Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology
Targovax and Valo Therapeutics intend to run pre-clinical proof-of-concept studies testing mutant RAS peptide coated ONCOS-102 adenovirus
Targovax ASA announces that its nomination committee has nominated Mr. Damian Marron for election as Chairman of the Board at the company's Annual General Meeting..
Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter 2019 results.
Targovax ASA announces that it has completed patient enrollment in the phase I trial with ONCOS-102 in combination with Keytruda in patients with advanced anti-PD1 checkpoint inhibitor refractory melanoma.
Targovax ASA, announces that clinical data from its combination trial with ONCOS-102 and Keytruda in anti-PD1 refractory melanoma was presented at the Society for Immunotherapy of Cancer Annual Meeting
Targovax ASA, a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces its third quarter 2019 results.
Targovax Selected for Oral Presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
Targovax ASA, announces that clinical data on the company's lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus which has been engineered to selectively infect and replicate in cancer cells, will be presented at the Society for Immunotherapy of Cancer Annual Meeting being held November 6-10, 2019, in Maryland, USA.